Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference58 articles.
1. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer;Murthy;New Engl. J. Med.,2020
2. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer;Modi;New Engl. J. Med.,2020
3. Heart failure after treatment for breast cancer;Boekel;Eur. J. Heart Fail.,2020
4. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer;Noronha;J. Clin. Oncol.,2020
5. Progress in conductive polyaniline-based nanocomposites for biomedical applications: a review;Zare;J. Med. Chem.,2020
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Disulfiram-loaded CuO2 nanocarriers for enhanced synergistic chemodynamic chemotherapy;Journal of Colloid and Interface Science;2024-11
2. Strategic chemical synthesis and application of nanocarriers responsive to the tumor microenvironment;Nano Today;2024-10
3. SECTM1 promotes the development of glioblastoma and mesenchymal transition by regulating the TGFβ1/Smad signaling pathway;International Journal of Biological Sciences;2024
4. Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress;European Journal of Pharmacology;2023-12
5. Advances in Polymeric Micelles: Responsive and Targeting Approaches for Cancer Immunotherapy in the Tumor Microenvironment;Pharmaceutics;2023-11-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3